FDA Approvals in Oncology: October-December 2025
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
Tag: Multiple myeloma
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
The countdown to the new year is nearly upon us, but no need to count down to the last...
In October 2025, AACR's journals editors highlighted studies on the anticancer function of an Alzheimer’s-related protein, small-molecule-drug conjugates, and...
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
This month, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.
Multiple myeloma can be tricky to treat, but many treatment options exist, and new research is constantly supporting more.
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...